Table 1.
Baseline characteristics.
| Variables | Patients (n = 324) |
|---|---|
| Age | 63.0 ± 10.6 |
| Men | 209 (64.5%) |
| Location | |
| Head | 168 (51.9%) |
| Body | 66 (20.4%) |
| Tail | 58 (17.9%) |
| Mixed | 32 (9.8%) |
| Antitumor treatment | |
| Operation | |
| Whipple procedure | 4 (1.2%) |
| PPPD | 47 (14.5%) |
| Total pancreatectomy | 1 (0.3%) |
| Distal pancreatectomy | 13 (4.0%) |
| Chemotherapy | 245 (75.6%) |
| Supportive care | 14 (4.3%) |
| Stage | |
| I | 4 (1.2%) |
| II | 89 (27.5%) |
| III | 61 (18.8%) |
| IV | 170 (52.5%) |
| CEMIP, ng/mL | 0.67 (0.40–1.08) |
| CA 19–9, U/mL | 410.5 (40.8–3342.5) |
| Overall survival | 314 days (169–581) |
Variables are expressed as mean ± standard deviation, median (interquartile range), or n (%). PPPD, pylorus-preserving pancreaticoduodenectomy; CEMIP, cell migration-inducing hyaluronan binding protein; CA 19-9, carbohydrate antigen 19-9.